Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has announced the conversion of NOK 2,000,000 worth of convertible bonds into 3,333,333 new shares at a price of NOK 0.6 each, increasing the company’s share capital to NOK 61,345,650. This conversion, requested by Atlas Special Opportunities, LLC, reflects Circio’s strategic financial maneuvers to bolster its capital structure and support its innovative biotechnology initiatives.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. The company has created a unique circular RNA vector expression platform, known as circVec, which enhances protein expression significantly compared to traditional mRNA systems. Circio is also working on a pan-RAS cancer vaccine, TG01, for KRAS driver mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,369,849
Current Market Cap: NOK64.29M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.